|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Sumitomo Pharmaceuticals America |
|---|---|
| Information provided by: | Sumitomo Pharmaceuticals America |
| ClinicalTrials.gov Identifier: | NCT00044005 |
Purpose
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: SM-13496 |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind, Dose Comparison, Parallel Assignment, Safety Study |
| Official Title: | A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 in Patients With Schizophrenia |
Eligibility| Ages Eligible for Study: | 18 Years to 64 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations| United States, California | |
| Optimum Health Services | |
| La Mesa, California, United States, 91942 | |
| Sharp Mesa Vista Hospital | |
| San Diego, California, United States, 92123 | |
| Institute for Psychopharmacology Research | |
| Cerritos, California, United States, 90703 | |
| Affiliated Research Institute | |
| San Diego, California, United States, 92108 | |
| United States, District of Columbia | |
| Comprehensive Neuroscience. Inc. | |
| Washington, District of Columbia, United States, 20016 | |
| United States, Florida | |
| Comprehensive Neuroscience. Inc. | |
| Melbourne, Florida, United States, 32935 | |
| Segal Institute for Clinical Research | |
| North Miami, Florida, United States, 33161 | |
| United States, Georgia | |
| Atlanta Center for Medical Research | |
| Atlanta, Georgia, United States, 30308 | |
| Carman Research | |
| Smyrna, Georgia, United States, 30080 | |
| United States, Hawaii | |
| Hawaii Research Center | |
| Honolulu, Hawaii, United States, 96826 | |
| United States, Illinois | |
| American Medical Research | |
| Oakbrook, Illinois, United States, 60523 | |
| United States, Maryland | |
| Centers for Behavioral Health, LLC | |
| Rockville, Maryland, United States, 20850 | |
| United States, New Jersey | |
| ClinSearch, Inc. | |
| Kenilworth, New Jersey, United States, 07033 | |
| Comprehensive Clinical Research CNS, PC | |
| Clementon, New Jersey, United States, 08021 | |
| United States, Pennsylvania | |
| Quantum Clinical Services Group | |
| Philadelphia, Pennsylvania, United States, 19139 | |
| United States, Texas | |
| FutureSearch Trials | |
| Austin, Texas, United States, 78756 | |
| Community Clinical Research | |
| Austin, Texas, United States, 78756 | |
| University Hills Clinical Research | |
| Dallas, Texas, United States, 75235 | |
| Claghorn Lesem Research Clinic, Inc. | |
| Bellaire, Texas, United States, 77401 | |
| United States, Virginia | |
| CNS, Inc. | |
| Falls Church, Virginia, United States, 22041 | |
| United States, Washington | |
| Northwest Clinical Research Center | |
| Belleview, Washington, United States, 98004 | |
More Information
| Study ID Numbers: | D1050174 |
| Study First Received: | August 16, 2002 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00044005 |
| Health Authority: | United States: Food and Drug Administration |
|
SM-13496 Schizophrenia |
|
Schizophrenia Mental Disorders Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
